Humacyte announced the publication of long-term clinical outcomes for its Symvess acellular tissue-engineered vessel (ATEV) in extremity arterial trauma repair in the Journal of Vascular Surgery Cases, Innovations and Techniques. The prospective study followed patients for up to 36 months after implantation in situations where an autologous vein graft was not feasible, providing some of the first long-term data for an off-the-shelf biologic conduit in this setting.
According to the published results, Symvess maintained structural integrity throughout follow-up with a 92.9 % infection-free rate from month 3 to month 36, and no infections occurring after day 37 of implantation. Limb salvage rates remained high despite the trauma cohort’s severity, with 87.3 % at 12 months and 82.5 % at 24 months. Adverse and serious adverse events declined over time, and importantly no deaths, amputations or spontaneous mechanical failures were attributed to the device during the observed period.
Symvess is designed as a universally implantable, bioengineered human tissue vessel intended to provide rapid revascularisation in adult patients with extremity arterial injuries, where urgent restoration of blood flow is needed and traditional vein grafts may be unavailable or impractical. The long-term data add to Symvess’s evidence base supporting durability, resistance to infection and sustained limb salvage outcomes in a challenging trauma population.
The publication represents a key milestone for Humacyte’s regenerative medicine platform, which aims to develop off-the-shelf biologic tissues for a range of clinical needs beyond trauma repair. Symvess has received full approval from the U.S. Food and Drug Administration for vascular trauma repair, reflecting its clinical significance and potential impact on patient care.
